State Street Corp Sells 2,600 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO)

State Street Corp lowered its position in Abeona Therapeutics Inc (NASDAQ:ABEO) by 1.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,295 shares of the biopharmaceutical company’s stock after selling 2,600 shares during the quarter. State Street Corp owned approximately 0.37% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Charles Schwab Investment Management Inc. bought a new stake in shares of Abeona Therapeutics in the 3rd quarter worth approximately $151,000. Bank of New York Mellon Corp raised its position in Abeona Therapeutics by 2.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares during the period. GSA Capital Partners LLP boosted its position in Abeona Therapeutics by 54.3% during the third quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 33,831 shares during the period. Simplify Asset Management Inc. purchased a new stake in Abeona Therapeutics during the second quarter valued at about $1,732,000. Finally, abrdn plc grew its stake in shares of Abeona Therapeutics by 158.8% during the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after buying an additional 200,647 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ABEO shares. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Stock Performance

Abeona Therapeutics stock opened at $5.91 on Friday. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The firm has a market cap of $256.91 million, a P/E ratio of -2.20 and a beta of 1.44. Abeona Therapeutics Inc has a 1-year low of $3.05 and a 1-year high of $9.01. The firm has a 50-day moving average of $6.01 and a 200-day moving average of $5.59.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.